1-4 of 4
Torsten Dahlen
Close
Sort by
Journal Articles

Effectiveness of Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) after Two or More Prior Tyrosine Kinase Inhibitors

Torsten Dahlén, Camille C.B. Kockerols, Germano Ferreira, Peter E. Westerweel, Jiri Mayer, Alex Allepuz, David Wormser, Lillian Yau, Daniela Žácková
Journal: Blood
Blood (2022) 140 (Supplement 1): 3889–3890.
https://doi.org/10.1182/blood-2022-163151
Published: 2022
Journal Articles

Treatment Patterns in Patients with Chronic Myeloid Leukemia in Chronic Phase in the Third Line of TKI Therapy and Beyond Based on Real-World Evidence

Torsten Dahlen, Camille Kockerols, Germano Ferreira, Peter E. Westerweel, Jiří Mayer, Tarek Sahmoud, David Wormser, Lillian Yau, Daniela Žácková
Journal: Blood
Blood (2021) 138 (Supplement 1): 1485.
https://doi.org/10.1182/blood-2021-148773
Published: 2021
Journal Articles

Overall Survival and Adverse Events in 378 Ibrutinib-Treated Patients with Chronic Lymphocytic Leukemia - a Swedish Register-Based Nationwide Study

Torsten Dahlen, Gustaf Edgren, Leif Stenke, Jingcheng Zhao
Journal: Blood
Blood (2021) 138 (Supplement 1): 3750.
https://doi.org/10.1182/blood-2021-148537
Published: 2021
Journal Articles

Increased Risk of Cardiovascular Events Associated with TKI Treatment in Chronic Phase Chronic Myeloid Leukemia. Data from Swedish Population-Based Registries

Torsten Dahlén, MD, Gustaf Edgren, MD PhD, Martin Höglund, MD PhD, Mats Lambe, MD PhD, Magnus Björkholm, MD PhD, Fredrik Sandin, PhD, Anders Själander, MD PhD, Johan Richter, MD PhD, Lotta Ohm, MD PhD, Magnus Bäck, MD PhD, Leif Stenke, MD PhD
Journal: Blood
Blood (2014) 124 (21): 3134.
https://doi.org/10.1182/blood.V124.21.3134.3134
Published: 2014